therapeutics

Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

BACKGROUND

Adalimumab, a TNF-α inhibitor, is widely used clinically. Recent studies suggest Adalimumab can improve muscle damage after ischemic stroke (IS), but its protective mechanisms remain unclear. This study investigates the effect of adalimumab on muscle structure post-IS and the role...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

Targeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

BACKGROUND

Type 2 diabetes mellitus (T2D) arises from the interplay between peripheral insulin resistance and pancreatic β-cell dysfunction, ultimately leading to impaired glucose utilization and chronic hyperglycemia. Despite therapeutic advances, the multifactorial nature of T2D continues to demand the development of...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

BACKGROUND

Cystinosis is a rare multisystem, autosomal recessive disease caused by dysfunction or loss of cystinosin (CTNS), which results in lysosomal cystine accumulation, primarily affecting the kidneys. Advances in renal transplantation, cysteamine treatment and improved medical care have increased life expectancy,...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAn Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

Anabolic Effects of Salbutamol Are Lost Upon Immobilization.

BACKGROUND

Periods of muscle disuse occur during hospitalization, illness or the recovery from (sports) injury and lead to a rapid loss of muscle mass and the development of insulin resistance. Salbutamol is a fast-acting β2-adrenoreceptor agonist that may improve muscle protein...

🗓️ 2025-11-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAnabolic Effects of Salbutamol Are Lost Upon Immobilization.

Sarcopenia and MASLD: novel insights and the future.

Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle...

🗓️ 2025-11-06
📰 Publication: Nature Reviews Endocrinology
Read MoreSarcopenia and MASLD: novel insights and the future.

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Lymphomas are common cancers affecting the lymphatic system. Chemotherapy is a standard treatment, yet its impact on patient's physical capacity remains understudied. This study aimed to evaluate changes in body composition, muscle strength, and physical performance in patients diagnosed with...

🗓️ 2025-11-04
📰 Publication: Hematological Oncology
Read MoreChanges in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Therapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.

Osteosarcopenia, characterized by the coexistence of osteopenia/osteoporosis and sarcopenia, represents a significant health concern in geriatrics, with an increased risk of falls and fractures. The enterokine fibroblast growth factor 19 (FGF19) was recently shown to prevent muscle weakness in preclinical...

🗓️ 2025-11-04
Read MoreTherapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.

Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

BACKGROUND

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

METHODS

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients...

🗓️ 2025-11-03
📰 Publication: Eclinicalmedicine
Read MoreEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

Jianpi Qiangji Granule ameliorates aging-associated sarcopenia via AMPK/PGC-1α axis in SAMP8 mice.

BACKGROUND

Sarcopenia is an age-related syndrome characterized primarily by the progressive decline of muscle mass and function. It is frequently associated with adverse outcomes such as falls, fractures, and hospitalization, often leading to substantial economic burdens and severe health hazards. At...

🗓️ 2025-11-01
📰 Publication: Phytomedicine
Read MoreJianpi Qiangji Granule ameliorates aging-associated sarcopenia via AMPK/PGC-1α axis in SAMP8 mice.

Role of Branched-Chain Amino Acids in Mitigating Osteosarcopenia: An Experimental Study Using Ovariectomised Mice Models.

BACKGROUND

Osteosarcopenia, characterised by concurrent bone loss and muscle atrophy, presents a significant challenge in aging populations, particularly in postmenopausal women. The current therapeutic options potentially treat bone and muscle loss independently, highlighting the importance of an integrated approach. This study...

🗓️ 2025-10-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRole of Branched-Chain Amino Acids in Mitigating Osteosarcopenia: An Experimental Study Using Ovariectomised Mice Models.

Advancing Single-Cell Transcriptomic Analysis to Reveal Age-Related Skeletal Muscle Changes: A Systematic Review.

Population aging has become a widespread health problem that leads to huge socioeconomic burden. Skeletal muscle as an important component of motor system, gradually degenerates with age. Age-related muscle disorders, such as sarcopenia is associated with higher risks of falls,...

🗓️ 2025-10-24
📰 Publication: Aging And Disease
Read MoreAdvancing Single-Cell Transcriptomic Analysis to Reveal Age-Related Skeletal Muscle Changes: A Systematic Review.

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

BACKGROUND

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of survival of motor neuron (SMN) protein inducing progressive muscle weakness and atrophy due to motor neurons degeneration. Despite benefits of SMN restoration therapies in patients, motor defects are...

🗓️ 2025-10-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDrug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Cistanche deserticola extract and its active components, echinacoside, ameliorate sarcopenia by activating the IGF-1/PI3K-AKT pathway to modulate ferroptosis.

BACKGROUND

Sarcopenia (SP) is characterized by progressive loss of skeletal muscle mass and function, and is a significant health burden in an aging society. Existing therapies have limited effectiveness. While ferroptosis plays a key role in sarcopenia, its regulatory mechanism remains...

🗓️ 2025-10-05
📰 Publication: Phytomedicine
Read MoreCistanche deserticola extract and its active components, echinacoside, ameliorate sarcopenia by activating the IGF-1/PI3K-AKT pathway to modulate ferroptosis.

GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma.

BACKGROUND

Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target....

🗓️ 2025-10-15
Read MoreGFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma.

CXCL14 Promotes Skeletal Muscle Mass Growth and Attenuates Lipopolysaccharide- and Dexamethasone-Induced Muscle Atrophy in Cultured Myotubes and Mouse Models.

BACKGROUND

Skeletal muscle mass is regulated by secretory factors derived from myofibers and muscle-resident cells. Identifying these factors and understanding their mechanisms is critical for combating muscle wasting disorders. This experimental study investigates the role of CXCL14, a chemokine primarily secreted...

🗓️ 2025-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCXCL14 Promotes Skeletal Muscle Mass Growth and Attenuates Lipopolysaccharide- and Dexamethasone-Induced Muscle Atrophy in Cultured Myotubes and Mouse Models.

The Novel MuRF2 Target SNX5 Regulates PKA Activity Through Stabilization of RI-α and Controls Myogenic Differentiation.

BACKGROUND

Muscle RING finger (MuRF) proteins are striated muscle-specific E3 ubiquitin ligases essential for muscle homeostasis. Whereas MuRF1 is well known for its role in muscle atrophy, MuRF2 and MuRF3 contribute to microtubule stabilization, influencing muscle differentiation and function. Their cooperative...

🗓️ 2025-01-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe Novel MuRF2 Target SNX5 Regulates PKA Activity Through Stabilization of RI-α and Controls Myogenic Differentiation.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!